Provided by Tiger Trade Technology Pte. Ltd.

Ligand Pharmaceuticals

280.18
-6.1100-2.13%
Post-market: 280.180.00000.00%19:30 EDT
Volume:158.24K
Turnover:44.66M
Market Cap:5.59B
PE:28.85
High:286.27
Open:286.27
Low:279.87
Close:286.29
52wk High:326.63
52wk Low:157.52
Shares:19.94M
Float Shares:19.35M
Volume Ratio:0.86
T/O Rate:0.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):9.71
EPS(LYR):6.13
ROE:21.96%
ROA:3.99%
PB:5.77
PE(LYR):45.71

Loading ...

Ligand initiated with a Buy at BofA

TIPRANKS
·
Mar 11

Ligand Pharmaceuticals CFO Octavio Espinoza Disposes of Common Shares

Reuters
·
Mar 07

Ligand Pharmaceuticals Director John W. Kozarich Disposes of Common Shares

Reuters
·
Mar 05

Ligand Pharmaceuticals (LGND) Is Up 8.1% After Swinging to Profit and Filing New Equity Shelf - What's Changed

Simply Wall St.
·
Mar 05

Ligand Pharmaceuticals (LGND) Profitability Boost From US$102.9m One Off Gain Tests Bull Case

Simply Wall St.
·
Feb 28

Xintong Pharmaceutical's IPO: Unstable Revenue, Halved R&D, Reduced Fundraising Targets Amid Intense Competition Clouding Commercial Prospects

Deep News
·
Feb 28

BRIEF-Ligand Pharmaceuticals Files For Mixed Shelf Offering

Reuters
·
Feb 28

Ligand files automatic mixed securities shelf

TIPRANKS
·
Feb 28

Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $277 From $275, Maintains Outperform Rating

MT Newswires Live
·
Feb 27

GUIDANCE: (LGND) Ligand Pharmaceuticals Expects 2026 Total Revenue Range $245M-$285M, vs. FactSet Est of $265.7M

MT Newswires Live
·
Feb 26

Ligand’s FY 2025 royalty revenue rises 48% to USD 161.0 million

Reuters
·
Feb 26

Ligand Pharmaceuticals Q4 Adj. EPS $2.02 Beats $1.56 Estimate, Sales $59.666M Beat $55.589M Estimate.

Benzinga Earnings
·
Feb 26

BRIEF-Ligand Pharmaceuticals Q4 EPS USD 2.12

Reuters
·
Feb 26

Ligand Pharmaceuticals Q4 Pretax Profit USD 56.78 Million

THOMSON REUTERS
·
Feb 26

Ligand Pharmaceuticals: Reiterates FY Guidance of $245-$285 Mln in Revenues & Adj EPS of $8.00-$9.00

THOMSON REUTERS
·
Feb 26

Ligand Pharmaceuticals: Expects 2026 Royalty Revenue to Be in Range of $200 Million to $225 Million

THOMSON REUTERS
·
Feb 26

Ligand Pharmaceuticals Q4 Basic EPS USD 2.27

THOMSON REUTERS
·
Feb 26

Ligand Reports Fourth Quarter and Full Year 2025 Financial Results

THOMSON REUTERS
·
Feb 26

Ligand Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Feb 25

Ligand price target raised to $239 from $231 at H.C. Wainwright

TIPRANKS
·
Feb 25